Recent Insights from the BioDay Registry

Real-world evidence (RWE) is essential to complement randomized controlled trials (RCTs). Although RCTs are important for assessing efficacy, their patient populations and outcomes often differ from those seen in daily clinical practice. RWE helps us understand long-term effectiveness and safety in broader, non-selected patient groups.^1,2

The BioDay registry, initiated in October 2017, provides valuable real-world insights. With more than 2,000 patients enrolled across around 20 centers in the Netherlands, it includes clinical data, patient reported outcomes, and information on atopic comorbidities.³

Expert Videos

Key study finding

Effectiveness and safety of dupilumab versus tralokinumab in atopic dermatitis: A propensity score– matched analysis from the BioDay registry⁴

In this oral presentation, Dr. Lian van der Gang reported the 52-week real-world data comparing dupilumab and tralokinumab in biologic and JAK inhibitor naive patients with moderate-to-severe atopic dermatitis from the BioDay registry.

Among 643 dupilumab and 107 tralokinumab patients (unadjusted/IPTW-cohort), both treatments improved EASI and itch scores, showing statistically significant difference in NRS itch. The differences in EASI and NRS-itch were more pronounced in incorporating discontinuation rates.

Discontinuations due to ineffectiveness were higher for tralokinumab versus dupilumab. The most frequent adverse events leading to discontinuation were BAOSD (Biologics Associated Ocular Surface Disease, dupilumab: 3,6%, tralokinumab: 4,7%) and hair loss (dupilumab: 0,6%, tralokinumab: 4,7%) as well as muscle or joint pain (dupilumab: 0,6%).

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK inhibitors in the BioDay Registry⁵

This publication presents real-world data from the Dutch BioDay registry on drug survival of biologics and JAK inhibitors in adults with atopic dermatitis. In the overall treatment episodes (TEs), dupilumab (n= 865) had the highest 2-year drug survival (77,3%), followed by upadacitinib (n=241; 63,5%), tralokinumab (n=227; 47,6%), baricitinib (n=106; 42,8%) and abrocitinib (n=144; 27,1%).

Ineffectiveness was the main reason for discontinuation. Higher baseline NRS-pruritus scores and the use of concomitant immunosuppressants were associated with shorter dupilumab drug survival.

Real-world efficacy and safety of dupilumab in prurigo nodularis: 52-week results from the BioDay registry⁶

This poster reports the 52-week real-world data from the Dutch BioDay registry on dupilumab in adults with moderate-to-severe prurigo nodularis (PN). Among 69 patients, dupilumab led to significant and continuous improvements in skin lesions, itch, and quality of life over 52 weeks.

The overall safety was consistent with the known dupilumab safety profile. Adverse events were mostly mild, with ocular surface disease (15.9%) arthralgia/myalgia (15.9%), and headache (11,6%) being the most frequent. A limited number of patients discontinued dupilumab due to ineffectiveness, pregnancy, or side effects.

Conclusion